Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.
You may also be interested in...
Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death
Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.
Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death
Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.
Merck KGaA Acquires Rights For Colorectal Cancer Therapy UFT From Taiho
Germany-based Merck says it has not decided whether it will seek FDA approval for the uracil/tegafur combination; FDA deemed UFT “not approvable” for advanced colorectal cancer in 2001, when Bristol held rights to the agent.